Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $115.00 Price Target at Piper Sandler

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective cut by Piper Sandler from $140.00 to $115.00 in a research report released on Monday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on RARE. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Wells Fargo & Company boosted their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, December 20th. Canaccord Genuity Group boosted their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. JPMorgan Chase & Co. cut their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. Finally, HC Wainwright reissued a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.71.

Ultragenyx Pharmaceutical Stock Up 0.8 %

RARE stock opened at $39.64 on Monday. The firm has a market capitalization of $3.67 billion, a PE ratio of -6.25 and a beta of 0.67. Ultragenyx Pharmaceutical has a twelve month low of $37.02 and a twelve month high of $60.37. The stock has a 50-day simple moving average of $42.23 and a two-hundred day simple moving average of $47.87.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The company had revenue of $164.88 million for the quarter, compared to analysts’ expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CAO Theodore Alan Huizenga sold 967 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $40,710.70. Following the completion of the sale, the chief accounting officer now owns 50,265 shares of the company’s stock, valued at approximately $2,116,156.50. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Emil D. Kakkis sold 11,727 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the sale, the chief executive officer now directly owns 2,183,985 shares of the company’s stock, valued at approximately $92,229,686.55. This trade represents a 0.53 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 136,370 shares of company stock worth $5,751,499. 5.80% of the stock is currently owned by insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its stake in Ultragenyx Pharmaceutical by 740.0% in the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock worth $4,802,000 after acquiring an additional 76,150 shares during the period. Atria Investments Inc purchased a new stake in Ultragenyx Pharmaceutical in the third quarter worth $269,000. Victory Capital Management Inc. lifted its stake in Ultragenyx Pharmaceutical by 8.8% in the third quarter. Victory Capital Management Inc. now owns 10,948 shares of the biopharmaceutical company’s stock worth $608,000 after acquiring an additional 884 shares during the period. KBC Group NV lifted its stake in Ultragenyx Pharmaceutical by 24.5% in the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 506 shares during the period. Finally, Natixis Advisors LLC lifted its stake in Ultragenyx Pharmaceutical by 290.0% in the third quarter. Natixis Advisors LLC now owns 52,562 shares of the biopharmaceutical company’s stock worth $2,920,000 after acquiring an additional 39,086 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.